Oncology Practice Management Issues


December 2018, Vol 8, No 12

MIPS: How to Be Successful Today and in the Future

Toni Gress

Practice Management

The McKesson value-based care team employs a combination of tactics to help practices in The US Oncology Network achieve success in the Merit-Based Incentive Payment System (MIPS). One of the challenges with the new MIPS program is the need to focus on the current year’s performance, while taking steps to ensure that practices are successful in future years. [ Read More ]

First-Line Olaparib a New Standard in Women with Newly Diagnosed, BRCA-Positive Advanced Ovarian Cancer?

Phoebe Starr

Ovarian Cancer

Long-term therapy with olaparib (Lynparza), a poly (ADP ribose) polymerase (PARP) inhibitor, in women with newly diagnosed advanced ovarian cancer and a BRCA1 or BRCA2 mutation led to a significant, unprecedented improvement in progression-free survival (PFS), reducing the risk for disease progression or death by 70% compared with placebo, according to results of the phase 3 SOLO-1 clinical trial. [ Read More ]

Daurismo New Treatment Approved for Older Adults with Acute Myeloid Leukemia

FDA Approvals, News & Updates, Leukemia

On November 21, 2018, the FDA approved glasdegib (Daurismo; Pfizer), an oral Hedgehog inhibitor, in combination with low-dose cytarabine (LDAC), for patients with newly diagnosed acute myeloid leukemia (AML) who are aged ≥75 years or who have comorbidities that preclude use of intensive induction chemotherapy. The FDA approved glasdegib using its priority review and granted it an orphan drug designation. [ Read More ]

Adcetris First FDA-Approved Drug for CD30-Expressing Peripheral T-Cell Lymphomas

FDA Approvals, News & Updates

On November 16, 2018, the FDA approved brentuximab vedotin (Adcetris; Seattle Genetics), in combination with chemotherapy, for patients with untreated systemic ­anaplastic large-cell lymphoma (sALCL) or with other CD30-­expressing peripheral T-cell lymphomas (PTCLs), including angioim­munoblastic T-cell lymphoma and PTCL not otherwise specified. This is the first FDA-approved drug for newly diagnosed PTCL, including sALCL. Brentuximab vedotin was previously approved by the FDA for classical Hodgkin lymphoma. [ Read More ]

Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer

Wayne Kuznar

Immunotherapy

The combination of immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) may soon represent a new first-line treatment option in patients with early-stage metastatic colorectal cancer (CRC) associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Two studies presented at the ESMO 2018 Congress demonstrated the efficacy of this combination in this patient population. [ Read More ]

Paradigm Shift: Radiation a New Standard in Prostate Cancer with Low Metastatic Burden

Phoebe Starr

Prostate Cancer

For patients with newly diagnosed metastatic prostate ­cancer, current standard management is androgen-deprivation therapy plus docetaxel (Taxotere). Contrary to previous assumptions, radiation to the primary tumor improves survival in men with low metastatic disease burden. This new finding came from the preplanned analysis of the multiarm, multistage STAMPEDE study presented at the ESMO 2018 Congress by lead investigator Chris C. Parker, MD, FRCR, MRCP, Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust, Sutton, England. The study was simultaneously published online in the Lancet.1 [ Read More ]

Targeted Intervention Reduces Opioid Use by Nearly 50% After Urologic Oncology Surgery

Meg Barbor, MPH

Symptom Management

Patients can be successfully managed with minimal opioid medication after urologic oncology surgery, said Kerri Stevenson, MN, NP-C, RNFA, CWOCN, Lead Advanced Practice Provider – Interventional Radiology, Stanford Health Care, CA, at the 2018 ASCO Quality Care Symposium. She presented results from a 4-month study conducted at Stanford Health Care. Over the course of the study, patients were able to decrease their opioid use after surgery by 46%, without compromising pain control. [ Read More ]